Clinical Trial Update: Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of GSK2820151 in advanced or recurrent solid tumors has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasms

Drugs mentioned

• GSK2820151

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer, Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2020-02-12